DA
Derek Archila Wells Fargo Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Celldex Therapeutics
CLDX
$1.52B
| $22.87 | $38 |
66%
upside
| Overweight |
20 Aug ‘25
18 days ago |
|
2
Soleno Therapeutics
SLNO
$3.71B
| $69.77 | $123 |
76%
upside
| Overweight |
20 Aug ‘25
19 days ago |
|
3
Sutro Biopharma
STRO
$89.9M
| $1.06 | $3 |
183%
upside
| Equal-Weight |
12 Aug ‘25
27 days ago |
|
4
Cabaletta Bio
CABA
$155M
| $1.70 | $2 |
18%
upside
| Equal-Weight |
8 Aug ‘25
1 month ago |
|
5
Ascendis Pharma
ASND
$12.5B
| $205.91 | $295 |
43%
upside
| Overweight |
8 Aug ‘25
1 month ago |
|
6
Zentalis Pharmaceuticals
ZNTL
$126M
| $1.75 | $5 |
186%
upside
| Equal-Weight |
7 Aug ‘25
1 month ago |
|
7
Viridian Therapeutics
VRDN
$1.53B
| $18.72 | $26 |
39%
upside
| Equal-Weight |
7 Aug ‘25
1 month ago |
|
8
Arvinas
ARVN
$575M
| $7.83 | $16 |
104%
upside
| Overweight |
7 Aug ‘25
1 month ago |
|
9
Incyte
INCY
$16.9B
| $86.64 | $89 |
3%
upside
| Overweight |
6 Aug ‘25
1 month ago |
|
10
argenx
ARGX
$45.9B
| $750.78 | $756 |
1%
upside
| Overweight |
31 Jul ‘25
1 month ago |
|
|
ALMS
11
Alumis Inc. Common Stock
ALMS
$469M
| $4.51 | $17 |
277%
upside
| Overweight |
25 Jul ‘25
1 month ago |
|
12
Rhythm Pharmaceuticals
RYTM
$6.78B
| $102.12 | $129 |
26%
upside
| Overweight |
10 Jul ‘25
2 months ago |
|
13
Kymera Therapeutics
KYMR
$3.11B
| $43.51 | $53 |
22%
upside
| Overweight |
26 Jun ‘25
2 months ago |
|
|
ATYR
14
aTyr Pharma
ATYR
$550M
| $5.61 | $25 |
346%
upside
| Overweight |
20 Jun ‘25
2 months ago |
|
15
Apellis Pharmaceuticals
APLS
$3.55B
| $28.13 | $29 |
3%
upside
| Equal-Weight |
2 Jun ‘25
3 months ago |
|
|
SEPN
16
Septerna, Inc. Common Stock
SEPN
$643M
| $14.43 | $18 |
25%
upside
| Equal-Weight |
16 May ‘25
3 months ago |
|
17
Nurix Therapeutics
NRIX
$758M
| $9.91 | $25 |
152%
upside
| Overweight |
9 Apr ‘25
5 months ago |
|
18
Monte Rosa Therapeutics
GLUE
$305M
| $4.94 | $10 |
102%
upside
| Equal-Weight |
21 Mar ‘25
5 months ago |
|
19
Q32 Bio
QTTB
$20.4M
| $1.67 | $15 |
798%
upside
| Equal-Weight |
12 Mar ‘25
5 months ago |
|
20
Exelixis
EXEL
$10.2B
| $37.88 | $36 |
5%
downside
| Equal-Weight |
24 Feb ‘25
6 months ago |
|
21
AnaptysBio
ANAB
$613M
| $21.90 | $51 |
133%
upside
| Overweight |
13 Feb ‘25
6 months ago |
|
22
Zymeworks
ZYME
$1.14B
| $15.05 | $14 |
7%
downside
| Equal-Weight |
19 Dec ‘24
8 months ago |
|
23
Kezar Life Sciences
KZR
$29.8M
| $4.07 | $9 |
121%
upside
| Equal-Weight |
19 Dec ‘24
8 months ago |
|
24
Immunovant
IMVT
$2.99B
| $17.14 | $45 |
163%
upside
| Overweight |
19 Dec ‘24
8 months ago |
|
25
C4 Therapeutics
CCCC
$194M
| $2.72 | $12 |
341%
upside
| Overweight |
19 Dec ‘24
8 months ago |
|